Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced it will present a poster on Leucine Enkephalin as a potential analgesic at PAINWeek 2021, being held on September 7-11, 2021 at The Cosmopolitan in Las Vegas, NV.
The following poster from Virpax will be presented on Thursday, September 9th from 6:30 p.m. – 8:30 p.m. PST:
Title: Enkephalin as a Potential Analgesic and CNS Modulator
Presenter: Jeffrey A. Gudin, MD, EVP, Chief Medical Officer of Virpax Pharmaceuticals
Abstract ID: 1090715 Poster No.: 29
For further information, please visit https://www.painweek.org/
“Drug overdose deaths in the U.S. rose nearly 30% in 2020. The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is supporting scientific solutions to stem the national opioid public health crisis,” stated Jeffrey Gudin, MD, co-founder and EVP, Chief Medical Officer of Virpax. “Our research is being funded through a collaborative research and development agreement with the National Institutes of Health-National Center for Advancing Translational Sciences (NIH-NCATS). I am delighted to serve as principal investigator for this promising molecule with multiple actions in the central and peripheral nervous system. To date, animal trials for Envelta have demonstrated comparable analgesia versus morphine without the development of opioid tolerance, respiratory depression, euphoria, or drug seeking behavior associated with the use of morphine,” concluded Dr. Gudin.
